Cargando…

Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak

In order to curb the rapid dissemination of the B.1.351 variant of SARS-CoV-2 in the district of Schwaz and beyond, the EU allocated additional vaccine doses at the beginning of March 2021 to implement a rapid mass vaccination of the population (16+). The aim of our study was to determine the seropr...

Descripción completa

Detalles Bibliográficos
Autores principales: Willeit, Peter, Kimpel, Janine, Winner, Hannes, Harthaller, Teresa, Schäfer, Helena, Bante, David, Falkensammer, Barbara, Rössler, Annika, Riepler, Lydia, Ower, Cornelia, Sacher, Magdalena, von Laer, Dorothee, Borena, Wegene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500479/
https://www.ncbi.nlm.nih.gov/pubmed/36159252
http://dx.doi.org/10.3389/fpubh.2022.989337
_version_ 1784795231571410944
author Willeit, Peter
Kimpel, Janine
Winner, Hannes
Harthaller, Teresa
Schäfer, Helena
Bante, David
Falkensammer, Barbara
Rössler, Annika
Riepler, Lydia
Ower, Cornelia
Sacher, Magdalena
von Laer, Dorothee
Borena, Wegene
author_facet Willeit, Peter
Kimpel, Janine
Winner, Hannes
Harthaller, Teresa
Schäfer, Helena
Bante, David
Falkensammer, Barbara
Rössler, Annika
Riepler, Lydia
Ower, Cornelia
Sacher, Magdalena
von Laer, Dorothee
Borena, Wegene
author_sort Willeit, Peter
collection PubMed
description In order to curb the rapid dissemination of the B.1.351 variant of SARS-CoV-2 in the district of Schwaz and beyond, the EU allocated additional vaccine doses at the beginning of March 2021 to implement a rapid mass vaccination of the population (16+). The aim of our study was to determine the seroprevalence of SARS-CoV-2 among the adult population in the district of Schwaz at the time of the implementation. Data on previous history of infections, symptoms and immunization status were collected using a structured questionnaire. Blood samples were used to determine SARS-CoV-2 specific anti-spike, anti-nucleocapsid and neutralizing antibodies. We recruited 2,474 individuals with a median age (IQR) of 42 (31–54) years. Using the official data on distribution of age and sex, we found a standardized prevalence of undocumented infections at 15.0% (95% CI: 13.2–16.7). Taken together with the officially documented infections, we estimated that 24.0% (95% CI: 22.5–25.6) of the adult population had prior SARS-CoV-2 infection. Hence, the proportion of undocumented infections identified by our study was 55.8% (95% CI: 52.7–58.5). With a vaccination coverage of 10% among the adults population at that time, we imply that a minimum of two-thirds of the target popuation was susceptible to the circulating threat when this unique campaign started.
format Online
Article
Text
id pubmed-9500479
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95004792022-09-24 Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak Willeit, Peter Kimpel, Janine Winner, Hannes Harthaller, Teresa Schäfer, Helena Bante, David Falkensammer, Barbara Rössler, Annika Riepler, Lydia Ower, Cornelia Sacher, Magdalena von Laer, Dorothee Borena, Wegene Front Public Health Public Health In order to curb the rapid dissemination of the B.1.351 variant of SARS-CoV-2 in the district of Schwaz and beyond, the EU allocated additional vaccine doses at the beginning of March 2021 to implement a rapid mass vaccination of the population (16+). The aim of our study was to determine the seroprevalence of SARS-CoV-2 among the adult population in the district of Schwaz at the time of the implementation. Data on previous history of infections, symptoms and immunization status were collected using a structured questionnaire. Blood samples were used to determine SARS-CoV-2 specific anti-spike, anti-nucleocapsid and neutralizing antibodies. We recruited 2,474 individuals with a median age (IQR) of 42 (31–54) years. Using the official data on distribution of age and sex, we found a standardized prevalence of undocumented infections at 15.0% (95% CI: 13.2–16.7). Taken together with the officially documented infections, we estimated that 24.0% (95% CI: 22.5–25.6) of the adult population had prior SARS-CoV-2 infection. Hence, the proportion of undocumented infections identified by our study was 55.8% (95% CI: 52.7–58.5). With a vaccination coverage of 10% among the adults population at that time, we imply that a minimum of two-thirds of the target popuation was susceptible to the circulating threat when this unique campaign started. Frontiers Media S.A. 2022-09-09 /pmc/articles/PMC9500479/ /pubmed/36159252 http://dx.doi.org/10.3389/fpubh.2022.989337 Text en Copyright © 2022 Willeit, Kimpel, Winner, Harthaller, Schäfer, Bante, Falkensammer, Rössler, Riepler, Ower, Sacher, von Laer and Borena. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Willeit, Peter
Kimpel, Janine
Winner, Hannes
Harthaller, Teresa
Schäfer, Helena
Bante, David
Falkensammer, Barbara
Rössler, Annika
Riepler, Lydia
Ower, Cornelia
Sacher, Magdalena
von Laer, Dorothee
Borena, Wegene
Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak
title Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak
title_full Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak
title_fullStr Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak
title_full_unstemmed Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak
title_short Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak
title_sort seroprevalence of sars-cov-2 infection in the tyrolean district of schwaz at the time of the rapid mass vaccination in march 2021 following b.1.351-variant outbreak
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500479/
https://www.ncbi.nlm.nih.gov/pubmed/36159252
http://dx.doi.org/10.3389/fpubh.2022.989337
work_keys_str_mv AT willeitpeter seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak
AT kimpeljanine seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak
AT winnerhannes seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak
AT harthallerteresa seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak
AT schaferhelena seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak
AT bantedavid seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak
AT falkensammerbarbara seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak
AT rosslerannika seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak
AT rieplerlydia seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak
AT owercornelia seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak
AT sachermagdalena seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak
AT vonlaerdorothee seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak
AT borenawegene seroprevalenceofsarscov2infectioninthetyroleandistrictofschwazatthetimeoftherapidmassvaccinationinmarch2021followingb1351variantoutbreak